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A B S T R A C T
Trichosporon fungemia is a life-threatening opportunistic infection that is increasing in frequency.
Invasive disease occurs almost exclusively in immunocompromised hosts, particularly in neutropenic
adults with hematological malignancies and uncommonly in children. We report the case of a pediatric
patient where disseminated trichosporonosis progressed while on micafungin, between treatments with
voriconazole and amphotericin B, demonstrating the difﬁculty with and importance of prolonged and
continuous treatment.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Trichosporon fungemia is an emerging opportunistic infection
that is increasing in frequency. The species T. asahii has been
known to cause invasive disease. This occurs most commonly in
those who are immunocompromised, usually neutropenic adults,
and uncommonly in children. We present the case and complicated
management of a pediatric patient with recently diagnosed acute
lymphoblastic leukemia who developed fatal disseminated T.
asahii after induction chemotherapy.
Case report
A 3-year-old previously healthy female presented to the
emergency room with a three-week history of chest pain, fatigue,
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4.0/).showed leukocytosis (42,300/L) and thrombocytopenia (91,000/L).
Pediatric hematology/oncology was consulted, and the patient was
ultimately diagnosed with acute lymphoblastic leukemia (ALL).
Induction chemotherapy was initiated with pegaspargase, vincris-
tine, and daunorubicin.
A week later the patient developed a fever along with
pancytopenia. Empiric coverage included vancomycin, cefepime,
and tobramycin. Forty-eight hours later blood cultures grew
Trichosporon spp. with sensitivity to voriconazole (VCZ) and
amphotericin B. Intravenous (IV) VCZ therapy was initiated at
180 mg every 12 h. Despite subsequent negative cultures, she
remained febrile intermittently. On hospital day 12 the patient
showed evidence of acute kidney injury, hypertension, and toxic
levels of both vancomycin (37.7 mg/m) and tobramycin (2.5 mg/
mL). Tobramycin and cefepime were replaced with meropenem
and vancomycin was replaced with linezolid to minimize kidney
injury. Voriconazole was discontinued secondary to concern for
renal toxicity, and micafungin was initiated.
The patient’s condition continued to deteriorate, and on day 23
the patient was intubated secondary to respiratory failure; she
remained on mechanical ventilation for the duration of her care.
The patient was noted to have multiple maculopapular skin lesions
(Fig. 1) involving her trunk and bilateral lower extremities that
were suggestive of fungal emboli. Skin biopsies obtained on day 29
(Figs. 2 and 3) revealed Trichosporon spp. and blood cultures grew
T. asahii.
At this time, infectious disease was consulted and antifungals
were changed to combination VCZ (80 mg IV twice daily) ande under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. Maculopapular lesions on the extremities of a pediatric patient with
disseminated trichosporonosis.
Fig. 3. PAS stained at 600 times magniﬁcation revealing fungal elements of patient
with disseminated Trichosporon asahii infection, including true hyphae,
pseudohyphae, arthroconidia, and blastospores.
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levels biweekly.
For the next two weeks, on combination treatment of VCZ and
amphotericin B liposome, the skin lesions slowly improved. All
cultures remained negative until day 49 when the patient
developed intermittent spiking fevers with urine cultures again
growing Trichosporon spp. On day 66 urine cultures were negative
for Trichosporon spp with blood and urine cultures remaining
negative for the duration of care. Skin biopsies were repeated to
monitor progression, and an umbilical lesion showed evidence of
fungal elements, though the clinical signiﬁcance was uncertain.
On hospital day 105 the patient expired secondary to extensive
end organ damage despite extraordinary measures. Although
treatment did not impact mortality, the fungemia had resolved on
VCZ as well as responded to combination VCZ and amphotericin B
emphasizing the importance of continued treatment even afterFig. 2. PAS staining at 600 times magniﬁcation from skin lesion, which revealed
budding yeasts and rare hyphae adjacent to fat.negative cultures. This case demonstrates the persistence of the
organism Trichosporon spp. as well as the difﬁculty with treatment.
Discussion
Over the past two decades the non-Candida yeasts, including
Trichosporon spp., have been increasingly associated with life-
threatening disease in immunocompromised individuals [1].
Profound granulocytopenia in patients with hematological malig-
nancies has been reported as the most common risk factor for
disseminated disease [2]. Additional predisposing factors include
organ transplantation, chronic kidney disease, intravenous cathe-
ters, chemotherapy, corticosteroid therapy, extensive burns,
prosthetic valve surgery, and peritoneal dialysis [1,2].
Trichosporon spp. are widely distributed in nature, predomi-
nantly in soil, and may be part of the normal biota of the skin, oral
cavity, respiratory tract, gastrointestinal tract, and vagina. The
genus currently consists of six species that are of clinical
signiﬁcance. T. asahii, as found in our patient, T. asteroides, and
T. mucoides are known to cause invasive infections. T. ovoides, T.
inkin, and T. cutaneum can cause white piedra while T. cutaneum
can also cause an allergic pneumonia [3].
Trichosporon spp. is known to colonize many different parts of
the body including the gastrointestinal system, respiratory system,
skin, and vagina. Invasive disease may be preceded by gastroin-
testinal colonization and translocation throughout the gut in those
with mucositis and enteritis from cytotoxic chemotherapy [3].
Repeated positive sputum cultures indicate colonization that could
progress toward pulmonary trichosporonosis in the neutropenic
patient, and can be conﬁrmed by microscopic examination of lung
biopsy specimens [4]. A shift to a prevalence of catheter-related
fungemia cases, without evidence of organ involvement, has also
been reported [5].
Trichosporon spp. can cause both superﬁcial and invasive
infection. The latter can be divided into disseminated and localized
forms. Disseminated disease is more common and typically
presents as an acute febrile illness that can rapidly to multi-organ
failure [3]. Skin lesions are found in about one-third of patients
with trichosporonosis. The cutaneous manifestations include
erythematous papules on the trunk and extremities. Over time,
the papules may develop bullae or central necrosis and resemble
eschars [6]. Patients with pulmonary involvement may have
dyspnea and a cough productive of bloody sputum. Chest
radiographs typically show diffuse inﬁltrates with an alveolar
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can occasionally cause renal damage and aggravation of renal
dysfunction [3].
In Trichosporon fungemia blood cultures are frequently positive.
Cultures of urine, sputum, cerebrospinal ﬂuid, and tissue have also
yielded the fungus [6]. Culture and histopathology of skin lesions
have also been helpful in establishing the diagnosis. Skin biopsies
show dermal invasion by hyphae and arthroconidia, and some
have shown thromboembolic vasculitis due to the organism [6]. It
should be emphasized that cultures of Trichosporon isolated from
sputum or urine may represent colonization rather than infection.
Despite advances in the treatment of fungemia, ﬁrst-line therapy
for trichosporonosis has yet to be determined [5]. Tentative
recommendations can be made based on in vitro susceptibility
data, but the optimal agent and duration of treatment is not known
[2]. Voriconazole, alone or in combination, is potentially the drug of
choice for disseminated disease [7]. Newer triazoles, such as
posaconazole and ravuconazole, have also shown potent in vitro
activity against Trichosporon spp. [8]. Those who cannot tolerate
voriconazole due to its side effects may use amphotericin B,
ﬂucytosine, ﬂuconazole, and itraconazole as alternatives, although
multidrug resistance to these has been reported [2]. Although
amphotericin B has shown some positive effectiveness to Trichos-
poron spp. in vitro, it functions poorly with breakthrough infections,
especially those seen in patients with profound neutropenia on high
doses of amphotericin B [9]. Echinocandins have excellent activity
against a broad spectrum of fungi including Aspergillus and Candida
species and have been selected in the setting of renal impairment as
they have minimal toxicity. They, however, are not effective in
treating Trichosporonosis nor should they be used prophylactically
as it has been reported that their use may select for resistant fungal
organisms [10].
The prognosis of trichosporonosis has been poor, with mortality
rates in excess of 80% [3]. To date, the only reported cures have
been patients who were either not neutropenic at the time of
diagnosis or who recovered from their neutropenia quickly [1]. In
patients with leukemia survival is thought to be primarily related
to bone marrow recovery [4]. If a patient recovers from
disseminated infection, maintaining chronic suppressive therapy
should be considered since late relapses have occurred. Oral
voriconazole is currently the easiest agent to use for this purpose
[11]. Ongoing suppressive therapy is particularly important for
those with endocarditis or central nervous system involvement.
Patients with chronic immunosuppressive conditions should
potentially continue therapy indeﬁnitely [11].
The high mortality rates associated with invasive infections
occur despite the availability of antifungals with less toxicity and
improved potency [9]. Early treatment has been related to better
outcomes, but this is dependent on diagnostic tests that are both
rapid and highly sensitive [12]. As traditional histology- and
culture-based methods have poor sensitivity and often only make a
diagnosis late when the fungal burden is high, research has turned
its focus to developing improved molecular and serological assays
[12]. Several Trichosporon-speciﬁc tests have been developed in the
last two decades, including PCR-based methods, ﬂow cytometry,
and proteomics [3]. Though these new assays are not yet
standardized to be used routinely in clinical settings, they
represent key strategies for future diagnostic validation [3].
In conclusion, Trichosporon species cause life-threatening
infections, particularly in neutropenic patients. Emerging infec-
tions are often difﬁcult to diagnose, are refractory to conventional
antifungal agents, and are associated with high mortality rates
[2,5]. Early detection of this unusual pathogen is essential toprovide speciﬁc timely antifungal therapy and improve the
patient’s chance of survival. Therefore, clinicians should have a
high index of suspicion for Trichosporon fungemia in patients with
aforementioned risk factors, particularly in those with hematologic
malignancies who have catheters in place. Removal of central
venous lines and control of underlying conditions should be
considered to optimize clinical outcomes [3]. This case illustrates
that once blood cultures grow Trichosporon, therapy with
voriconazole or combination therapy with voriconazole and
amphotericin B should be utilized for prolonged treatment.
Despite a better side effect proﬁle echinocandins are ineffective
for both eradication and maintenance.
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